Atea Pharmaceuticals Inc. (AVIR), a clinical-stage biopharmaceutical company developing oral antiviral therapeutics for serious viral diseases, has an upcoming clinical trial event next month that is worth keeping an eye on.
The first interim analysis of the company's SUNRISE-3 trial by an independent Data Safety Monitoring Board (DSMB) for safety and futility is expected this March.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com